Weiran Feng, PhD

Icon

Assistant Professor

Member, Cancer Epigenetics Institute

Research Program

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427

Educational Background

  • Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, NY Ph.D. 08/2018 Genetics, Molecular Biology 
  • Peking University, Beijing, China B.S. 07/2011 Biological Sciences

Honors & Awards

  • 2023 K99/R00: Pathway to Independence Award
  • 2023 PCF Young Investigator Award
  • 2019 Department of Defense Early Investigator Research Award
  • 2019 Anna D. Barker Basic Cancer Research Fellowship (declined)
  • 2018 Weintraub Graduate Student Award candidate
  • 2012 Olayan Fellowship Award, Memorial Sloan Kettering Cancer Center
  • 2009-2010 Headmaster Fellowship, Peking University
  • 2008-2009 Fang Ruixian Scholarship, Peking University
  • 2006 Gold Medal Award of China National Biology Olympiad

Selected Publications

Feng W*, Ladewig E*, Salsabeel N, Zhao H, Lee YS, Gopalan A, Luo H, Kang K, Fan N, Rosiek E, Masilionis I, Chaligne R, de Stanchina E, Chen Y, Carver BS, Leslie CS, Sawyers CL. (2023) ERG-driven prostate cancer emerges from basal-luminal hybrid cells. BioRxiv.

https://www.biorxiv.org/content/10.1101/2023.05.15.540839v1.full

• Prostate cancer (PCa) is the most frequent cancer and the second leading cause of cancer death among American men. The oncogenic ERG translocation (activating the ERG transcription factor) occurs in 50% of PCas. However, how ERG drives PCa remains unclear.

• To gain mechanistic insights, I performed single-cell profiling and lineage tracing in an autochthonous ERG-driven PCa model, combined with organoid modeling and fresh cell transplantation to delineate cell fate decisions at an early stage of disease initiation.

• Contrast to the striking luminal histology of PCa, I discovered that ERG does not initiate cancer from luminal cells, but from a subset of basal cells via a highly proliferative basal-luminal intermediate state that retains the ability to rapidly differentiate to luminal cells 

• My studies: • Discovered the previously overlooked heterogeneity within prostate basal cells. 

• Defined the intermediate state as a key transition in PCa initiation. 

• Helped resolve the preexisting debate about the cell of origin of PCa. 

• I led the study, while the co-first author Erik Ladewig provided computational expertise..

2. Feng W*, Cao Z*, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Rivera AA, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, Jasin M, Sawyers CL. (2021) Rapid interrogation of cancer cell of origin through CRISPR editing. Proc Natl Acad Sci., 118 (32) e2110344118.. https://pubmed.ncbi.nlm.nih.gov/34353917/ • The increasing complexity of different cell types revealed by single-cell analysis of tissues presents challenges in efficiently elucidating their functions. 

• I developed a rapid and efficient approach to CRISPR edit freshly isolated primary prostate cells or organoids. • Large intrachromosomal (∼2 Mb) or multigenic deletions can be engineered efficiently without the need for selection. 

• The freshly edited cells can be directly transplanted to host prostates as an edited population without any intermediate culture step, allowing for rapid generation of genetic models in vivo from an expanded repertoire of cell types. 

• I developed the approach and led the study, while the co-first author Zhen Cao implemented the approach for a subset of applications.

3. Feng W, Jasin M. (2018) 53BP1 nuclear body-marked replication stress in a human mammary cell model of BRCA2 deficiency. BioRxiv, 462119. https://www.biorxiv.org/content/10.1101/462119v1.abstract • Elucidated the causes and consequences of replication stresses upon BRCA2 inactivation.

 • As the single junior author on the paper, I led the study and performed all experiments..

4. Feng W, Jasin M. (2017) BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination. Nat Commun., 8, 525. PMCID: PMC5597640. https://www.ncbi.nlm.nih.gov/pubmed/28904335 

• BRCA2 is a well-known breast and ovarian tumor suppressor that functions by maintaining genome integrity. Given the tissue tropism of BRCA2-mutated cancers, key insights on the tumor suppressor function of BRCA2 are lacking due to a paucity of genetic models from a normal and disease-related background. • I engineered the first series of BRCA2 conditional knockout models in a non-transformed human mammary cell line. 

• I discovered for the first time a DNA under replication-53BP1 nuclear body formation-G1 arrest axis as the primary source of genome instability of BRCA2 deficiency. • BRCA2 loss confers hypersensitivity to PARP inhibition. BRCA2 plays a key role in two processes: a well-known homology-directed repair, and a newly recognized replication fork protection pathway. Knowledge on how each repair pathway contributes to genome integrity is critically needed for improving therapy responses.

 • I dissected BRCA2 functions by creating complementary separation-of-function systems 

• I demonstrated that replication stress and cell lethality due to BRCA2 deficiency is mainly attributed to a lack of homology-directed repair, but not replication fork protection, providing clear answers to a heavily debated topic. 

• As the single junior author on the paper, I led the study and performed all experiments..

Open Positions

About the Training Environment

As one of the four original cancer centers to receive comprehensive designation from the National Cancer Institute, Fox Chase Cancer Center has been at the forefront of cancer research for almost 90 years. We are home to excellent research facilities, top clinicians and scientists, and outstanding patient care. Our singular focus on cancer, which couples discovery science with state of the art clinical care and population health, remains the foundation of our work.

The scientist training programs at Fox Chase Cancer Center provide professional development opportunities in four core areas identified as crucial for successful careers in science, research, and health care including communication, leadership, teaching, and mentorship. Upon joining the program, graduate students and postdocs develop individual development plans to help guide their growth. Training throughout the year is supplemented with free professional development opportunities, including a robust ‘How To’ series, writing courses, networking, mentorship, and teaching opportunities, a trainee-led seminar series, a trainee-led annual Research Conference, and more. Postdocs at Fox Chase Cancer Center are supported by the Temple University Postdoc Association and the Office of Academic Affairs at Fox Chase, and are compensated with competitive pay and benefits.

In addition to the robust training program, scientists at Fox Chase Cancer Center benefit from being part of the rich scientific and biotech environment in the Philadelphia region. Many of our former trainees are now employees (and contacts) at nearby institutions and companies, including The Wistar Institute, Merk, GSK, AACR, and numerous others.

 

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...